Invivyd begins Phase 3 trial comparing COVID antibody to mRNA vaccine

June 9, 2026 7:01 AM

Invivyd Inc. (NASDAQ: IVVD) announced that the first participants have been dosed in its LIBERTY Phase 3 clinical trial, which ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found